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Summary
Follicular lymphoma is a slow-growing disease exhibiting
a heterogeneous clinical course, with a subset of patients
experiencing a rapid disease course in the first two years
and some developing disease transformation to a more ag-
gressive phenotype. The advent of highly effective ther-
apies has resulted in an increasing number of patients who
achieve long-term progression-free survival alongside a
good quality of life. Monoclonal antibodies, such as ritux-
imab, either alone or in combination with chemotherapy re-
gimens or radioimmunotherapy have been used with signi-
ficant improvements in outcome. New treatment strategies
such as new antibodies, biologic agents or vaccination ther-
apy are also under investigation for the treatment of re-
lapsed or refractory disease, further expanding the avail-
able options for patients and physicians alike. This article
presents an overview of the current therapeutic strategies
for the management of follicular lymphoma, focusing on
the issues encountered in clinical practice.
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Introduction
Follicular lymphoma is the most commonly-occurring
form of indolent lymphoma, and accounts for 20–25% of
all lymphomas [1]. The majority of patients initially
present with disseminated disease that follows a relatively
indolent clinical course. Follicular lymphoma is character-
ised by response to treatment with disease-free or asymp-
tomatic disease intervals, alternating with recurrence/pro-
gression and may transform to aggressive lymphoma at a
rate of around 3% per year [2].
This article provides an overview of the current treatment
strategy for follicular lymphoma. Given the large spectrum
of available data, the aim of this review is to discuss some
of the key issues which are encountered in clinical practice
relating to first-line and maintenance therapy, and the treat-
ment of relapsed/refractory follicular lymphoma.
Diagnosis and staging of follicular
lymphoma
Complete staging of follicular lymphoma at diagnosis is
an essential first step in making the appropriate therapeutic
decision, to individualise therapy and to evaluate the pa-
tient response to treatment [3]. Most follicular lymphoma
patients present with small- to medium-sized superficial
lymph nodes which may have been neglected for prolonged
periods of time [2]. The majority of follicular lymphoma
cases are diagnosed through histological examination of
such lymph nodes, with bone marrow involvement found
in approximately 60% of patients [2]. At initial diagnosis,
excisional lymph node biopsies of accessible lymph nodes
should be analysed by a haematopathologist experienced
in lymphoma diagnosis [4]. Fine-needle aspiration biopsies
are not deemed appropriate for the initial diagnosis of fol-
licular lymphoma [5]. In addition, initial tumour staging
also involves the use of computed tomography (CT) scans,
examination of bone marrow aspirates and biopsies by im-
munohistochemistry [5]. In cases of disseminated disease
or large tumour bulk, positron emission tomography (PET)
can be a useful tool to guide the choice of biopsy site [6].
However, routine use of PET is not yet recommended in
patients with follicular lymphoma with the possible excep-
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tion of confirming localised stage I/II disease [7]. Tumour
staging is performed according to the Ann Arbor system
[5].
Follicular lymphoma is thought to originate from germinal
centre B cells and retains its characteristic gene expression
profile [8]. Morphologically, follicular lymphoma is com-
posed of clonally related centrocytes (small cells) and
centroblasts (large cells), and is divided into three grades
based on the number of large B cells present [8]. In grades
1 and 2, the proportion of small cells is predominant,
whereas grade 3 features a greater proportion of large cells.
In grade 3A, centrocytes are still present whereas grade 3B
follicular lymphoma is composed entirely of large blastic
cells (table 1) [9]. Differences in genetic characteristics and
clinical behaviour suggest that grade 3A follicular lymph-
oma may be more indolent and related to grades 1 and 2,
whereas grade 3B is often associated with poor outcomes
and appears to be more closely related to diffuse large
B-cell lymphoma (DLBCL) [10]. There is some contro-
versy surrounding the clinical relevance and reproducibil-
ity of this grading system, with many experts arguing in
favour of considering grades 1 and 2 follicular lymphoma
(which share a similar indolent clinical behaviour and out-
come of treatment) as a single disease entity, with a dis-
tinction only at grade 3, which is generally considered as
an aggressive disease (in particular grade 3B) and usu-
ally treated with doxorubicin-containing regimens [11–13].
Histological assessment of the disease usually follows the
World Health Organisation (WHO) guidelines [14–16] as a
basis for lymphoma grading. The presence of a diffuse area
of large blastic cells in a follicular lymphoma of any grade
is equivalent to DLBCL and a separate diagnosis should be
made [16–18].
Prognostic systems
The first prognostic system specific to follicular lymphoma
was developed by the Italian Lymphoma Intergroup (ILI)
in the late 1990s [19]. Currently, the Follicular Lymphoma
International Prognostic Index (FLIPI) [20] is deemed to be
more applicable across a range of clinical settings [21–25]
and is still commonly used. Both systems were developed
prior to the introduction of monoclonal antibody therapy,
which has profoundly changed the treatment and outcome
of follicular lymphoma [26]. Hence, the FLIPI-2 was re-
cently developed, in a prospective series of patients need-
ing treatment, using parameters which were not previously
amenable to retrospective analysis, and may represent a
promising new tool for the identification of follicular
lymphoma patients with different risk profiles in the era
of immunochemotherapy [27]. A detailed discussion of the
prognostic parameters used for follicular lymphoma is bey-
ond the scope of this review, but the reader can refer to a
number of recent publications on this subject [28, 29]. The
FLIPI and FLIPI-2 indexes are summarised in table 2.
Table 1: Follicular lymphoma grading according to the WHO classification (modified after Harris et al. [14]).
Grading Definition
Grade 1–2 (low grade) 0–15 centroblasts per hpf*
1 0–5 centroblasts per hpf
2 6–15 centroblasts per hpf
Grade 3 >15 centroblasts per hpf
3A Centrocytes present
3B Solid sheets of centroblasts
Pattern Proportion follicular
Follicular >75%
Follicular and diffuse 25–75%
Focally follicular <25%
Diffuse 0%**
* hpf = high power field of 0.159 mm2
** Diffuse areas containing >15 centroblasts per hpf are reported as DLBCL with FL (grades 1 to 2, 3A, or 3B). Note that in small biopsies the absence of follicles may
reflect a sampling error
Table 2: The FLIPI [25] and FLIPI-2 [31] prognostic indexes for FL.
FLIPI (retrospective analysis; pre-rituximab era) FLIPI-2 (prospective analysis; rituximab era)
Age <60 years vs. ≥60 years Age <60 years vs.≥60 years
Haemoglobin ≥12g/dL vs. <12g/dL Haemoglobin ≥12g/dL vs. <12g/dL
Serum LDH ≤ULN vs. >ULN Serum β-2
microglobulin
≤ULN vs. >ULN
Ann Arbor stage I-II vs. III-IV Bone marrow
involvement
absent vs. present
5 factors
No. of nodal sites ≤4 vs. >4
5 factors
Longest diameter
of largest lymph
node
≤6 cm vs >6 cm
Risk group No. of factors 5–year OS 10–year OS Relative risk Risk group No. of factors 3–year PFS 3–year OS 5–year PFS
Good 0–1 91% 71% 1 Good 0 91% 99% 79%
Intermediate 2 78% 51% 2.3 Intermediate 1–2 69% 96% 51%
Poor ≥3 53% 36% 4.3 Poor ≥3 51% 84% 20%
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Watch and wait
Despite initially presenting with advanced stage disease,
most follicular lymphoma patients do not have symptoms
and/or a high tumour burden requiring immediate treatment
at the time of diagnosis, and in many cases the disease re-
mains indolent for many years without therapy [30, 31].
For the past 30 years, lymphoma experts have debated how
to manage patients with indolent lymphoma who have a
low tumour burden and no symptoms [32]. Clinical trials
addressing the issue of immediate chemotherapy versus
watchful waiting in asymptomatic advanced follicular
lymphoma have demonstrated no difference in overall sur-
vival (OS) [33]. A recent trial testing the benefits of imme-
diate rituximab treatment versus waiting until disease pro-
gression prior to initiating treatment, may be critical for
resolving these issues. Initial results from this trial showed
that early treatment with rituximab significantly delays the
need for new therapy but a more prolonged follow up will
be needed to understand whether this approach may alter
the natural history of the disease. So far no benefit has
been shown for OS [34]. Preliminary results from a quality
of life (QOL) analysis from this trial showed that patients
who received treatment with rituximab had reduced anxi-
ety and improved functional well-being [35]. At baseline,
patient QOL scores were similar or superior to those of
the general population (as assessed by the FACT-G ques-
tionnaire), with the exception of inferior emotional well-
being. Although patients on watch and wait also reported
improvements in some QOL parameters, the greatest im-
provements in emotional and functional well-being were
observed in patients who received either rituximab main-
tenance or monotherapy [35].
Whether early treatment of follicular lymphoma results in a
decreased risk of transformation is a matter of debate. The
evidence for this is conflicting, with some studies showing
no difference in the risk of transformation between patients
treated at diagnosis compared to those who did not receive
immediate treatment [33, 36, 37], and other studies show-
ing the opposite result [38]. It is important to note that these
comparisons were made using treatment regimens other
than immunochemotherapy, thereby calling into question
their relevance for today’s clinical practice. Although most
physicians would not hesitate to begin therapy in those pa-
tients with symptomatic or rapidly progressing disease, the
challenge is how to identify the asymptomatic patients who
may benefit from immediate treatment. Clinicians have to
rely on disease parameters (i.e. extent of tumour burden,
presence of B symptoms, bone marrow involvement) and
patient characteristics (i.e. age, presence of co-morbid con-
ditions) to guide them in making this decision. The pro-
gnostic value of FLIPI was confirmed in patients who had
undergone immunochemotherapy but it only gives an ap-
proximate evaluation of the expected outcome. Novel bio-
markers may soon become available for the prediction of
the disease course in the single patient, thus allowing in-
dividualised therapeutic approaches. However, research on
their use in the current era of immunochemotherapy is still
in the exploratory stages [39].
First-line treatment
The decision to start first-line treatment depends not only
on the stage but also on the symptoms of the disease [7].
The Swiss Group for Clinical Cancer Research (SAKK)
has included patients in their trials if at least one of the
following signs is present: B symptoms; symptomatic en-
larged lymph nodes or spleen; steady, clinically significant
progression of lymphadenopathy, splenomegaly or other
follicular lymphoma lesions documented by a 50% in-
crease in size over a period of at least 6 months; involve-
ment of at least 3 nodal sites (>3 cm), bulky disease
(>7 cm), haemoglobin <10g/dL, and platelets <100 x 109/L
due to bone marrow infiltration or splenomegaly [40].
The treatment of newly-diagnosed follicular lymphoma is
challenging, primarily because of the variability in disease
course and response to treatment. At present, the choice of
first-line therapy depends upon several factors: 1) clinic-
al characteristics (age, tumour stage, nodal sites involved,
Hb, LDH), 2) tumour physical characteristics, such as size
and rate of growth, 3) patient characteristics, such as age
and co-morbidities, 4) the goal of treatment (i.e., long last-
ing remission vs. palliation) [30, 32] and finally, 5) the an-
ticipated side-effects which are closely linked to the kind of
drug used and might include hair-loss, fatigue, risk of neut-
ropenic fever and polyneuropathy, to name the most pre-
dominant. It is worthwhile noting that the FLIPI, currently
used to predict the risk of treatment failure and to stratify
patients in clinical trials, has never been validated as a tool
for deciding when treatment is needed (patients with low
risk FLIPI may be symptomatic and patients with high risk
FLIPI may not necessarily need immediate treatment).
Radiation therapy
Clinically, 15–30% and pathologically, less than 10% of
follicular lymphoma patients present with stage I or II dis-
ease. Involved-field radiation therapy (RT) has resulted in
long-term control of the disease and a possible cure in a
subset of patients [41, 42]. Clinical data have suggested
that up to 40% of stage I and limited stage II patients may
achieve a durable remission through the use of RT [41, 43]
and that a reduction of the radiation field to involved nodes
has no negative impact regarding progression-free surviv-
al (PFS) and OS [44]. These results are encouraging with
respect to long-term disease control, a possible cure for
this subset of patients and reduced long-term toxicity with
smaller irradiated volumes. However, there is no standard
protocol for radiotherapy since the field size of radiother-
apy and the dose applied varied substantially in these trials.
Not surprisingly, PFS was influenced by tumour size and
Ann Arbor stage [41]. Advani et al. [45] demonstrated that,
in stage I and II follicular lymphoma patients, over half of
the subjects who did not receive any therapy remained un-
treated at a median of 6 or more years, and survival was
comparable to that seen in studies using immediate treat-
ment.
In stage III and IV patients with low disease burden, low
doses (15–32 Gy) of total lymphoid irradiation have res-
ulted in good response rates and remission times. Radio-
therapy has been shown to confer lasting disease remission
with relatively low toxicity [46]. However, despite the high
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degree of radiosensitivity of indolent lymphomas, little
data are available regarding the optimal treatment regimen
including optimal dose and radiotherapy volume, as well
as for comparing long-term outcomes of radiotherapy to
immunochemotherapy regimens. Currently, radiotherapy is
not the treatment of choice for newly-diagnosed follicular
lymphoma patients [41, 47–49] with stage III/IV disease in
most Swiss centres. However, it may be an option for se-
lected patients, for example for those who do not qualify
for systemic treatment (see below).
Immunochemotherapy
For the majority (~80%) of follicular lymphoma patients
who present with advanced disease requiring therapy, the
advent of monoclonal antibodies and their incorporation
into follicular lymphoma treatment regimens has greatly
improved survival and patient outcomes [50]. Rituximab
(MabThera®/Rituxan®) is a chimaeric monoclonal anti-
CD20 antibody that is currently used as a single agent and
also in combination with standard chemotherapy regimens
for the treatment of B-cell lymphoma, including follicular
lymphoma.
Single agent rituximab has also been shown to result in
high response rates and prolonged remission periods. An
initial study of rituximab monotherapy in 49 newly-dia-
gnosed patients with Stage II, III or IV follicular lymphoma
revealed good response rates (73% at four weeks post-
therapy). Interestingly, long-term follow-up data revealed
that patients showing a molecular response to rituximab
(BCL-2 negativity) experienced longer PFS (37 months,
versus 12 months for BCL-2 positive patients) [51, 52].
The median PFS was 23.5 months overall, 28.6 months for
responders, and 37 months for those showing molecular re-
sponse. Results from a study by the SAKK have sugges-
ted that individual factors predictive of event-free survival
(EFS) following single agent rituximab treatment include
low disease bulk ( <5 cm), Ann Arbor stage < IV, lim-
ited number of previous therapies, and prolonged rituximab
treatment [40, 53, 54].
There is a large body of clinical evidence demonstrating the
superiority of combining rituximab with nearly any chemo-
therapy regimen compared to the chemotherapy regimen
alone [55–58], thus moving this regimen to the forefront
of first-line therapies for follicular lymphoma. Currently,
there is some discussion over which partner chemother-
apy regimen is most suitable for use alongside rituximab.
The number of rituximab applications usually corresponds
to the number of chemotherapy cycles applied and ranges
between four and eight [55, 58]. Encouraging results from
an initial Phase II trial [59] triggered additional pivotal
studies exploring the benefits of combining rituximab with
standard chemotherapy regimens, including CHOP [57],
CVP [58], FCM [55], MCP [56, 60] and bendamustine
[61] (table 3). Amongst the anthracycline-based regimens,
CHOP is the most widely-used [62–64], while the CVP re-
gimen is more often applied to elderly patients requiring
treatment [65]. Bendamustine is an alkylating agent ap-
proved in Switzerland for the treatment of chronic lymph-
ocytic leukaemia (CLL), and bendamustine plus rituximab
has also been shown to be at least as effective as CHOP
plus rituximab as a first-line therapy in patients with in-
dolent non-Hodgkin lymphoma (NHL) [66]. In fact, the R-
bendamustine regimen was associated with a remarkable
improvement of a median PFS of 54.8 months compared to
34.8 months with R-CHOP (p = 0.0002) [61]. The combin-
ation of rituximab with several other chemotherapy regi-
mens such as MCP [56] and fludarabine [67] has also been
studied, albeit to a lesser extent. Regardless of the chemo-
therapy regimen, the use of rituximab has resulted in en-
hanced OS, disease control (as assessed by PFS, EFS, time
to progression [TTP], time to treatment failure [TTF]) and
response rates, as evidenced by a recent meta-analysis eval-
uating immunochemotherapy versus chemotherapy alone
[68]. An analysis of 1,943 NHL patients revealed a 0.65
pooled hazard ratio for death (95% confidence intervals
[CI]: 0.54–0.78) in favour of immunochemotherapy. Sim-
ilar findings were seen in the subgroup of 1,480 follicular
lymphoma patients (hazard ratio 0.63; 95% CI: 0.51–0.79).
Maintenance therapy
Despite the improved outlook for follicular lymphoma pa-
tients using effective first-line therapies, most patients ex-
perience relapses which necessitates the use of other well-
tolerated treatment strategies to extend the duration of re-
mission. One approach for achieving this goal is mainten-
ance therapy.
One agent that has been explored for use in maintenance
therapy is interferon (IFN) alpha [69, 70]. Although there is
evidence that interferon alpha improves PFS and possibly
OS when given together with chemotherapy [71], a meta-
analysis of data from the pre-rituximab era suggest that
the addition of interferon-alpha as maintenance therapy
for follicular lymphoma improves progression-free surviv-
al while the benefit for OS is less evident [69, 70]. In a
Table 3: Commonly used induction therapy regimens in FL.
Treatment Treatment
status
Summary of results References
R-CHOP First line patients Improvements in TTF (p <0.001), remission rate (p = 0.011), response duration (p <0.001), time to next
chemotherapy (p <0.001), and OS (p = 0.016), compared to CHOP alone
[53]
R-CVP First line patients Improvements in overall and complete response (p <0.0001), TTP (p <0.0001), and TTF (p <0.0001), compared
to CVP alone
[54]
R-MCP First line patients Improvements in overall and complete response (p = 0.0009, p = 0.004, respectively), EFS (p = 0.0001), PFS (p
<0.0001), and OS (p = 0.0278), compared to MCP alone
[56]
R-bendamustine First line patients Improvements in CR (p = 0.0323), PFS, EFS and TTNT (p = 0.0002) over R-CHOP. No differences in OS or
overall response.
[57]
R-FCM Relapsed/
refractory
patients
Improvements in PFS (p = 0.0381), OS (p = 0.0030), and overall response (p = 0.01), compared to FCM alone [51]
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recent report, pooled data from different randomised stud-
ies of the German Low Grade Lymphoma Study Group
suggest that IFN-maintenance prolongs remission duration
also after rituximab-containing induction treatments [72].
Nevertheless, any benefits of maintenance therapy with in-
terferon has to be balanced against its significant toxicity
that has a major impact on the patient's quality of life [69,
70, 73].
Rituximab, on the other hand, has seen growing use in
maintenance therapy regimens over the past years for sev-
eral reasons. Firstly, it has a good tolerability profile with
no significant long-term or cumulative toxic effects. Se-
condly, its long half-life enables the clinician to maintain
drug exposure while minimising the number of drug infu-
sions. Finally, the rituximab target (CD20) is usually still
expressed on the surface of residual lymphoma cells, in-
creasing the chances of successful re-treatment [74].
One of the earliest studies showing the clinical benefits of
rituximab maintenance therapy in follicular lymphoma was
a Phase III trial by Ghielmini et al [54]. In this trial run
by the SAKK (35/98 trial), newly-diagnosed (treatment-
naive) and previously-treated follicular lymphoma patients
received rituximab induction consisting of four weekly
doses (375 mg/m²). Non-progressing patients were ran-
domised to either observation with no further treatment or
prolonged rituximab administration (four rituximab infu-
sions every two months). Long-term results showed that a
substantial proportion of patients experienced long-term re-
mission following prolonged rituximab exposure [40]. The
median EFS was 24 months for the rituximab mainten-
ance arm, compared to 13 months for the observation arm
(p <0.001). In a multivariate Cox regression analysis, pro-
longed rituximab treatment was the only favourable pro-
gnostic factor (hazard ratio (HR) 0.59; 95% CI: 0.39 to
0.88; p = 0.009), suggesting that this maintenance regimen
could be used regardless of previous treatment, disease
stage or Fc receptor phenotype [40].
Since then, there has been a growing body of evidence
demonstrating the clinical advantages of rituximab main-
tenance therapy following various induction regimens, in-
cluding chemotherapy with or without rituximab [75–78].
The European Organisation for Research and Treatment
of Cancer conducted one of the pivotal Phase III trials in
patients with relapsed or refractory follicular lymphoma
(EORTC; 20891 trial). The study demonstrated the benefits
of rituximab maintenance every three months for two years
following chemotherapy or immunochemotherapy [76].
Compared to observation alone, rituximab maintenance
yielded significant improvements in PFS after CHOP (me-
dian 42.2 vs. 11.6 months; p <0.0001) and R-CHOP (me-
dian 51.8 vs. 23.0 months; p <0.0043). OS after the second
randomisation was also significantly improved: 85% at 3
years versus 77% with observation (HR, 0.52; p <0.011).
With a longer-term follow up, the superior PFS was con-
firmed but the improvement in OS no longer reached stat-
istical significance. This was possibly due to the unbal-
anced use of rituximab in the post-protocol salvage treat-
ment [77]. A similar prolongation of response duration
with rituximab maintenance therapy in patients with re-
lapsed and refractory follicular and mantle cell lymphoma
after combined immunochemotherapy (rituximab, fluda-
rabine, cyclophosphamide and mitoxantrone) was also
shown in a Phase III trial run by the German Low Grade
Lymphoma Study Group (GLSG) [55].
Based on the encouraging results in patients with relapsed
and refractory follicular lymphoma, the Primary RItuximab
and MAintenance (PRIMA) trial run by the Groupe d'Etude
des Lymphomes de l'Adulte (GELA) was designed to eval-
uate the effects of a two-year rituximab maintenance regi-
men every two months, compared to observation only, fol-
lowing various first-line immunochemotherapy regimens
[79]. Interim results at 25 months post-randomisation in-
dicated that rituximab maintenance conferred significant
PFS benefits (Hazard ratio 0.50; 95% CI: 0.39–0.64), but
no effect on OS was seen. An additional follow-up will al-
low evaluation of a possible effect on OS. According to
the authors of the present review, rituximab induction fol-
lowed by rituximab maintenance can be re-used when the
relapse occurs later than 1.0–1.5 years after the end of the
last rituximab maintenance therapy, although this needs to
be validated in future studies. A summary of the Phase III
studies with rituximab maintenance is provided in table 4.
Although the benefits of rituximab maintenance therapy
are widely accepted, issues on the appropriate timing, dos-
ing and duration remain to be clarified. The optimal dura-
tion of rituximab maintenance treatment is currently under
investigation in the SAKK 35/03 trial, in which patients
(who received rituximab induction consisting of four
weekly doses) receive rituximab maintenance every two
months for either eight months or for a maximum of five
years, or until progression or unacceptable toxicity [80].
Table 4: Phase III studies with rituximab maintenance in FL patients.
Group/Study Induction regimen Treatment
Setting
Patients Rituximab maintenance Total
rituximab
infusions
Results
SAKK 35/98 [44] Rituximab Any line N = 202 4 infusions every 2 months 4 Median EFS
13 vs. 24 months (p <0.001)
ECOG 1496 [74] CVP First-line N = 228 4 weekly infusions every 6 months for 2
years
16 Median PFS
1.3 vs. 4.3 years (p <0.0001)
PRIMA [80] CHOP, CVP, FCM +
rituximab
First-line N = 1018 Infusion every 2 months for 2 years 12 PFS at 2 years
66 vs. 82 % (p <0.0001)
EORTC 20981 [76] CHOP +/- rituximab Relapsed/
resistant
N = 334 Infusion every 3 months for 2 years 8 Median PFS
1.3 vs. 3.7 years (p <0.001)
GLSG [128] FCM + rituximab Relapsed/
refractory
N = 81 4 weekly infusions 3 and 9 months after
induction
8 Median response duration
26 months vs. not reached
(p = 0.035)
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Consolidation therapy
The goal of consolidation therapy is to rapidly improve
the response to first-line therapy by attaining complete re-
sponse (CR) from partial response (PR), and, where pos-
sible, by achieving a molecular response [81, 82]. By elim-
inating minimal residual disease, the hope is to minimise
the risk of relapse. Two of the main consolidation strategies
are myeloablative therapy prior to autologous stem cell
transplantation (SCT) and radioimmunotherapy (RIT).
Autologous SCT
Consolidation regimens consisting of myeloablative treat-
ment followed by SCT were frequently explored in fol-
licular lymphoma patients before the advent of rituximab
therapy [83]. Recently, SCT consolidation after induction
with R-CHOP was tested in a cohort of follicular lymph-
oma patients undergoing first remission, resulting in a five-
year PFS rate of 79% [84]. Results from another study
suggested that greater improvements in PFS and OS could
be attained in patients undergoing transplantation earlier in
the course of disease [85]. Long-term follow-up data sug-
gest that myeloablative therapy with autologous bone mar-
row transplantation confers prolonged freedom from recur-
rence, reaching a plateau at around 12 years. Nevertheless,
the toxicity of this treatment regimen has called into ques-
tion its practical relevance in the rituximab era. The use of
SCT as a consolidation treatment is restricted to younger,
fit patients who do not respond to first line treatment [86],
excluding its application in the wider follicular lymphoma
patient population including those >60 years of age [87].
Radioimmunotherapy
Radioimmunotherapy combines the specificity of a mono-
clonal antibody directed against a tumour antigen with a ra-
dioisotope that is delivered to tumour sites [88]. Clinical
data is available for the Yttrium-90 (90Y) – labelled murine
antibody ibritumomab tiuxetan (Zevalin®) and the Iod-
ine-131 (131I) – labelled antibody tositumumab (Bexxar®).
90Y ibritumomab tiuxetan has been studied in several Phase
II trials and in one recently-completed Phase III trial, the
First-line Indolent Trial (FIT) [89–93]. The results from
the FIT study showed that after chemotherapy, consolida-
tion treatment with 90Y ibritumomab tiuxetan had benefi-
cial effects on PFS. However, no significant effects were
observed in the subset of patients who received immun-
ochemotherapy as induction treatment [93], and only few
patients (13%) in the FIT study received 90Y ibritumomab
tiuxetan after immunochemotherapy. Two Phase II studies
suggest that this consolidation strategy can also be active in
the setting of rituximab-based induction treatment [94, 95].
Currently, Zevalin® is registered in Switzerland for consol-
idation treatment of follicular lymphoma following induc-
tion therapy.
131I tositumumab has also been evaluated as consolidation
therapy following various induction regimens (reviewed in
Gregory et al. [96]), and is only approved in the US for
the treatment of relapsed/refractory indolent lymphoma.
However, the use of radio-iodinated antibodies for treating
B-cell lymphomas has met with some reluctance, particu-
larly because of the potential for separation of the radio-
isotope and its subsequent accumulation in the thyroid.
Nevertheless, promising results have been obtained with
131I tositumumab in follicular lymphoma, with high re-
sponse rates (95%) and up to 75% complete responders
after first-line therapy [97]. It is important to note that the
patient cohort in this study consisted of individuals with
a favourable prognostic profile. 131I tositumumab has also
been successfully employed for myeloablation prior to re-
infusion of autologous peripheral stem cells, achieving an
overall response rate of 90% and an estimated two-year
PFS rate of 81% [98]. More long-term clinical studies in-
cluding data after immunochemotherapy are needed to gain
a better understanding of how 131I tositumumab and 90Y ib-
ritumomab tiuxetan can be properly incorporated into the
mainstream treatment strategies for follicular lymphoma.
Treatment of relapsed / refractory
follicular lymphoma
As conventional therapy for follicular lymphoma is not
curative, virtually all patients will at least develop a pro-
gressive or recurrent disease. Since transformation to a
higher grade histologic subtype is an integral part of the
natural history of follicular lymphoma, a repeated biopsy
is strongly recommended before initiating re-treatment of
the relapsed disease. This is particularly true for patients
presenting with clinical signs or symptoms suggesting
transformation, including rapid progression of lymphaden-
opathy, infiltration of uncommon extranodal sites, devel-
opment of B-symptoms, elevated serum lactate dehydro-
genase, and/ or hypercalcaemia.
In general, the treatment options for relapsed or refractory
disease are similar to those for first-line therapy [4]. Like-
wise, not all patients with progressive or relapsed disease
will necessarily require immediate therapy and asympto-
matic patients might be followed closely for development
of symptomatic disease or rapid progression. For patients
in need of treatment, there is no accepted standard therapy.
Therefore, practice varies greatly within the wide range
of available treatment options including re-challenge of
the initial treatment regimen (including rituximab as single
agent), use of a non-cross-resistant chemotherapy scheme
(preferably within a clinical trial) with or without ritux-
imab, RIT with radio-labelled antibodies, and high dose
chemotherapy with autologous or allogeneic SCT. In addi-
tion, involved-field or extended-field radiotherapy alone or
in combination with systemic therapy may be an option.
The choice of therapy is driven by factors similar to those
used to guide initial treatment, namely the extent and ag-
gressiveness of the tumour burden including its clinical
features, the characteristics of the patient [30, 32], as well
as the efficacy of prior treatment regimens [7]. Patients
who have a response duration significantly less than the ex-
pected mean PFS for the initial treatment regimen may be
considered eligible for more aggressive therapy, such as the
use of autologous SCT. These factors, in combination with
the therapeutic goals, form the basis for selecting a treat-
ment regimen when facing relapsed/ refractory disease.
The clinical practice guidelines set by the European So-
ciety for Medical Oncology (ESMO) recommend the use
of a non-cross resistant regimen (for example, the use of
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fludarabine after CHOP therapy) for relapses occurring in
<12 months [7]. For patients with a duration of remission
>6 months, ESMO guidelines recommend the inclusion
of rituximab. Due to the generally indolent nature of the
disease and the time frames in which disease progression
occurs, there is some degree of overlap when defining
“relapsed” versus “refractory” disease with regards to pre-
vious therapy. For clinical decision-making, we consider a
patient to be refractory if disease symptoms recur less than
6 months following the last treatment.
Immunochemotherapy
An important issue for patients who relapse after initial
rituximab treatment is the actual efficacy of rituximab re-
treatment. Whereas the superiority of combined immuno-
chemotherapy over chemotherapy alone has clearly been
demonstrated in a large randomised trial of relapsed and re-
fractory follicular lymphoma patients who had not previ-
ously received anthracycline or rituximab [76], the role of
rituximab re-treatment in patients who had previously been
treated with a rituximab-containing regimen has been sys-
tematically addressed in only a few underpowered trials to
date.
Taken together, the available clinical data suggest that the
majority of patients can benefit from a rituximab-contain-
ing regimen in the event of relapsed disease. Therefore, for
most patients with relapsed follicular lymphoma treatment
(or re-treatment) with rituximab, either alone or in combin-
ation with chemotherapy, is used. For patients with a poor
performance status, single agent rituximab may be prefer-
able due to its relatively low toxicity profile, while pa-
tients with a good performance status may prefer combin-
ation therapy for its superior response rates despite greater
toxicity and a lack of evidence in improving OS rates.
The development of novel antibodies may provide addi-
tional treatment options in this clinical setting in the near
future.
Radioimmunotherapy
Radioimmunotherapy is another therapeutic option in the
relapsed setting. In addition to their roles in consolidation
therapy, 131I tositumumab, 90Y ibritumomab tiuxetan (as
discussed in the previous section) as well as 131I rituximab
have been explored for the treatment of relapsed follicular
lymphoma. In a Phase III study of rituximab-naive patients
who had recurrent disease following chemotherapy, 90Y ib-
ritumomab tiuxetan treatment resulted in statistically signi-
ficant higher ORR and CR rates compared to rituximab as
a single agent, although duration of response (14.2 vs. 12.1
months) and time to progression (11.2 vs. 10.1 months)
were not significantly different [99]. A single-arm Phase
II study in 54 patients with rituximab-refractory follicular
lymphoma achieved ORR and CR rates of 74% and 15%,
respectively, upon treatment with 90Y ibritumomab
tiuxetan [100]. Another Phase II study of 131I tositumumab
in 40 patients with progressive disease resulted in ORR
and CR rates of 65% and 38%, respectively [101]. In a 10
year clinical experience study with 142 patients with in-
dolent NHL (mainly consisting of follicular lymphoma pa-
tients), the treatment of relapsed or refractory patients with
131I rituximab resulted in ORR and CR rates of 67% and
50%, and with median PFS and OS rates of 39 months and
87 months, respectively [102]. 131I tositumumab is not ap-
proved in Europe at present.
Autologous and allogeneic SCT
The use of autologous or allogeneic SCT in follicular
lymphoma remains controversial. The marked survival be-
nefits conferred by other treatment regimens have shifted
the clinical focus away from SCT as a treatment option.
Regarding autologous transplantation, the high incidence
of bone marrow involvement in advanced stage follicular
lymphoma raises doubts regarding potential contamination
of the stem cell product. In general, prospective data on
the long-term clinical benefits of autologous SCT in the
treatment of relapsed follicular lymphoma are lacking, and
most of the data available from transplant studies were
gathered in the pre-rituximab era. Thus far, the only pro-
spective randomised trial in relapsed follicular lymphoma
is the Conventional chemotherapy, Unpurged, Purged auto-
graft (CUP) trial run by the European Bone Marrow Trans-
plant (EBMT) Registry [103]. Results from this study that
included only a limited number of patients show a PFS and
OS advantage of high-dose therapy followed by autolog-
ous SCT over conventional chemotherapy. However, the
first-line treatment used in this patient cohort did not in-
clude rituximab, and the role of autologous SCT has not yet
been properly studied in the current immunotherapy era.
An extensive retrospective analysis of 254 patients ( <61
years of age) with relapsed follicular lymphoma was per-
formed by the GELA, and showed that event-free surviv-
al was best (67%) in patients who received rituximab-con-
taining salvage therapy and autologous SCT [104]. This
trend was apparent but did not reach statistical significance
in patients who had already received rituximab-containing
salvage therapy. In a retrospective review, Rohatiner et al.
demonstrated that autologous SCT may result in prolonged
survival without progression in nearly half of the patients,
with a greater benefit for patients intensified in second re-
mission, compared to those intensified later in the course of
the disease [85]. The EBMT reported long-term outcomes
on 693 patients with relapsed follicular lymphoma under-
going autologous SCT. With a median follow-up of 10.3
years, the 10–year PFS and OS rates were 31% and 52%,
respectively. At a median of 7 years, 9% of patients had de-
veloped a second malignancy [105]. More recently, a study
evaluated the effects of in vivo purging with rituximab and
rituximab maintenance therapy (every three months for two
years) in patients with relapsed follicular lymphoma under-
going high-dose therapy with BEAM conditioning [106].
The five-year PFS in patients receiving rituximab purging
and maintenance therapy was improved compared to those
receiving no therapy (54.8% versus 37.6%; p = 0.05), sug-
gesting that incorporating rituximab into in vivo purging
alongside maintenance treatment regimens may improve
the outcome of SCT patients. Finally, Phase II studies have
tested the feasibility of including RIT with high-dose ther-
apy plus SCT [107]. Toxicity appeared acceptable and a
retrospective comparison suggested longer survival times
with this approach rather than with total body irradiation-
based autologous SCT.
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The theoretical advantages of allogeneic SCT include the
absence of tumour contamination in the stem cell harvest
and a potential immunologic graft-versus-tumour effect.
However, the use of allogeneic SCT is hampered by the
high transplant-related mortality rates (as high as 40%)
which makes this option only feasible in young and fit pa-
tients [108]. With the goal of reducing the toxicity of allo-
geneic transplantation, reduced-intensity conditioning regi-
mens have increasingly been used and retrospective series
or single centre experiences suggest promising results with
this approach [109, 110]. However, prospective and multi-
centre trials are needed to confirm these results, and in gen-
eral, the long-term benefits of allogeneic and autologous
SCT need to be further assessed before these treatments can
be integrated into widespread clinical practice. We suggest
that patients with follicular lymphoma who are candidates
for autologous or allogeneic SCT be referred for a form-
al transplantation evaluation at first relapse or when they
do not respond to first-line immunochemotherapy. This is
particularly true for patients who experience relapse within
two years of first-line therapy or while still receiving ritux-
imab maintenance therapy.
New agents
Although a large proportion of follicular lymphoma pa-
tients respond to immunochemotherapy, there is a group
of patients with resistant/refractory disease for whom there
is a need for new agents to overcome the poor prognosis.
There are three main groups of novel therapeutic agents: i)
other monoclonal antibodies (novel anti-CD20 antibodies
such as ofatumumab [111] and GA 101 [112] or antibod-
ies against targets other than CD20), ii) agents that target
signal transduction pathways (e.g., proteasome inhibitors
[113]; Bcl-2 and Bcl-6 inhibitors), and iii) agents that target
the non-neoplastic cells of the tumour microenvironment
(immunomodulatory drugs e.g., lenalidomide [114]). Up-
coming phase III studies will demonstrate if targeted ther-
apies can further improve follicular lymphoma treatment.
Patient follow-up
In a disease with a long, unpredictable clinical course such
as follicular lymphoma, long-term follow-up is essential
for monitoring disease status regardless of the success of a
therapeutic regimen. In addition, long-term follow up could
provide valuable information on the impact of a particular
treatment programme upon the patient’s responsiveness to
future therapies [30].
There are no prospective, randomised trials comparing
various follow-up schedules. ESMO guidelines recom-
mend that follicular lymphoma patients undergo a medical
history and physical examination every three months for
two years, every four to six months for the following three
years, and then twice a year [7]. Patient examinations
should focus on the presence of tumour transformation
or secondary malignancies, such as secondary leukaemia.
Blood counts and routine biochemical testing including
measurement of LDH levels are recommended every six
months for the initial two years, but should be performed
in cases where disease progression is suspected. In such
cases, patients are strongly advised to undergo tumour re-
staging. When imaging results give rise to a suspicion of
relapse, a biopsy should be performed to confirm the pres-
ence of relapsed disease. Histopathologic examination al-
lows confirmation of transformation to more aggressive
disease. The role of routine imaging in the longitudinal
follow-up of asymptomatic patients after response assess-
ment is uncertain.
Metabolic imaging techniques including 18–fluoro-deoxy-
glucose PET in combination with CT are currently being
explored for tumour staging and in patient follow-ups
[115]. Computed tomography scanning alone is suitable for
pre-treatment staging of tumours, but is less specific for as-
sessing tumour response after therapy [116–118]. Although
CT scanning can be used to determine the size and loca-
tion of tumours, it cannot be used to differentiate between
viable tumours and scar tissue. PET can be used to distin-
guish between viable tumours and necrotic or fibrotic re-
sidual tissue masses following treatment [119, 120], but it
is associated with a proportion of false-positive and false-
negative findings. A recent analysis of 277 scans from a
subset of 160 patients enrolled in a large phase III study of
untreated follicular lymphoma (PRIMA study) was presen-
ted at the annual meeting of the ASH 2010, showing that
PET-CT can be a helpful predictor of PFS and comple-
ments response evaluation after first line therapy [121]. Pa-
tients with PET negativity showed prolonged PFS wheth-
er in conventional CR or PR. The heterogeneous nature of
follicular lymphoma highlights the need for large clinic-
al studies evaluating the accuracy and specificity of new
imaging techniques before they can be incorporated into
routine patient follow-ups.
Conclusions
The availability of anti-CD20 monoclonal antibodies has
led to significant improvements in the clinical outcome
of follicular lymphoma patients. Previously, the median
survival of follicular lymphoma patients from diagnosis
was 10 years [122], but patient survival has been extended
in the last decades [26, 50]. However, this improvement
began before the widespread introduction of anti-CD20
monoclonal antibodies in clinical practice and is likely a
result of the sequential application of effective new ther-
apies and improved supportive care. At present, despite re-
cent advances in our understanding of the biology of fol-
licular lymphoma, the heterogeneity of this disease remains
a confounding factor in the quest to alter its natural his-
tory. Although anti-CD20 monoclonal antibodies have re-
volutionised the treatment of follicular lymphoma, their
optimal method of administration remains to be defined.
A proportion of patients still do not respond to or become
refractory to rituximab-containing therapy. New anti-CD20
monoclonal antibodies and a variety of targeted treatments
are indeed under development and trials studying prognost-
ic biomarkers are ongoing. Improved treatment strategies
may therefore become available in the future. Nevertheless,
the prolonged natural course of the disease will require
long-term follow-up data on safety and efficacy for a prop-
er evaluation of any novel therapeutic approaches [26].
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